Karyopharm Therapeutics Inc. (KPTI)
| Market Cap | 14.63M-88.8% |
| Revenue (ttm) | 146.62M |
| Net Income | -224.74M |
| EPS | -14.33 |
| Shares Out | 22.68M |
| PE Ratio | n/a |
| Forward PE | -0.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 737,955 |
| Open | 0.65 |
| Previous Close | 0.65 |
| Day's Range | 0.63 - 0.69 |
| 52-Week Range | 0.62 - 10.99 |
| Beta | 1.04 |
| Analysts | none |
| Price Target | 7.25(+1024.03%) |
| Earnings Date | Nov 3, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$KPTI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in KPTI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KPTI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KPTI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
KPTI Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Accumulated deficit | $1.85B | 94.10% |
| Cash, cash equivalents and investments | $65.10M | 3.31% |
| Minimum liquidity covenant amount | $25.00M | 1.27% |
| Principal payment due under our senior secured term loan | $15.80M | 0.80% |
| Aggregate interest payments due | $10.10M | 0.51% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New KPTI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KPTI from public contracts
Source: USAspending.gov
KPTI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from KPTI’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score